ATE263559T1 - Zubereitungen enhaltend eine nitroneverbindung für die verwendung bei der behandlung von uveitis - Google Patents

Zubereitungen enhaltend eine nitroneverbindung für die verwendung bei der behandlung von uveitis

Info

Publication number
ATE263559T1
ATE263559T1 AT97921289T AT97921289T ATE263559T1 AT E263559 T1 ATE263559 T1 AT E263559T1 AT 97921289 T AT97921289 T AT 97921289T AT 97921289 T AT97921289 T AT 97921289T AT E263559 T1 ATE263559 T1 AT E263559T1
Authority
AT
Austria
Prior art keywords
uveitis
compound
nitronic
treatment
preparations containing
Prior art date
Application number
AT97921289T
Other languages
English (en)
Inventor
Kenneth W Narducy
Efraim Duzman
John Michael Carney
Allan Lee Wilcox
Original Assignee
Centaur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centaur Pharmaceuticals Inc filed Critical Centaur Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE263559T1 publication Critical patent/ATE263559T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
AT97921289T 1996-04-23 1997-04-23 Zubereitungen enhaltend eine nitroneverbindung für die verwendung bei der behandlung von uveitis ATE263559T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1627696P 1996-04-23 1996-04-23
PCT/US1997/006604 WO1997039751A1 (en) 1996-04-23 1997-04-23 Compositions comprising a nitrone compound for use in treating ocular inflammation

Publications (1)

Publication Number Publication Date
ATE263559T1 true ATE263559T1 (de) 2004-04-15

Family

ID=21776304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97921289T ATE263559T1 (de) 1996-04-23 1997-04-23 Zubereitungen enhaltend eine nitroneverbindung für die verwendung bei der behandlung von uveitis

Country Status (13)

Country Link
US (2) US5972977A (de)
EP (1) EP0910370B1 (de)
JP (1) JP2000509375A (de)
CN (1) CN1219130A (de)
AT (1) ATE263559T1 (de)
AU (1) AU721531B2 (de)
CA (1) CA2252494A1 (de)
DE (1) DE69728536T2 (de)
IL (1) IL126725A0 (de)
NO (1) NO984920L (de)
NZ (1) NZ332561A (de)
TW (1) TW450952B (de)
WO (1) WO1997039751A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
US6255353B1 (en) * 1998-03-13 2001-07-03 Centaur Pharmaceuticals, Inc. Inhibition of angiogenesis
PT1077694E (pt) * 1998-05-19 2004-12-31 Renovis Inc Produtos terapeuticos de arilnitrona para o tratamento da doenca inflamatoria dointestino
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
WO1999059569A1 (en) 1998-05-19 1999-11-25 Centaur Pharmaceuticals, Inc. Benzamide therapeutics for the treatment of inflammatory bowel disease
US6197826B1 (en) 1998-07-17 2001-03-06 Centaur Pharmaceuticals, Inc. α-(2-hydroxyphenyl) nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation
UA66401C2 (en) * 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
AU5601300A (en) * 1999-06-09 2000-12-28 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
FR2846968B1 (fr) * 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153722A (en) * 1977-10-06 1979-05-08 William H. Rorer, Inc. Method of treatment
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
ATE110565T1 (de) * 1989-10-17 1994-09-15 Oklahoma Med Res Found Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
EP0590072B1 (de) * 1991-06-18 2001-12-05 Oklahoma Medical Research Foundation Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
US5455272A (en) * 1993-10-22 1995-10-03 Oklahoma Medical Research Foundation Spin trap nitronyl hindered phenols

Also Published As

Publication number Publication date
CA2252494A1 (en) 1997-10-30
DE69728536T2 (de) 2005-02-24
WO1997039751A1 (en) 1997-10-30
AU2736697A (en) 1997-11-12
NO984920L (no) 1998-12-23
NZ332561A (en) 2001-01-26
US6140356A (en) 2000-10-31
IL126725A0 (en) 1999-08-17
NO984920D0 (no) 1998-10-22
TW450952B (en) 2001-08-21
DE69728536D1 (de) 2004-05-13
US5972977A (en) 1999-10-26
JP2000509375A (ja) 2000-07-25
EP0910370B1 (de) 2004-04-07
EP0910370A1 (de) 1999-04-28
AU721531B2 (en) 2000-07-06
CN1219130A (zh) 1999-06-09

Similar Documents

Publication Publication Date Title
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69718053D1 (de) in vitro methoden und verwendung von pharmazeutische zusammensetzungen für die BEHANDLUNG VON INNENOHRHAARZELLEN
DK0725779T3 (da) Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
CY2473B1 (en) New phenanthridines.
DE69429524D1 (de) Aminocyclohexylester und ihre anwendung
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE263559T1 (de) Zubereitungen enhaltend eine nitroneverbindung für die verwendung bei der behandlung von uveitis
DK0536182T3 (da) Fremgangsmåde til behandling af alopecia
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE60040616D1 (de) Verfahren zur behandlung maligner zellen eines patienten und pharmazeutische zusammensetzung zu dessen anwendung
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
DE69132575D1 (de) Sampangin-derivate zur verwendung als antimykotische und antimykobakterielle wirkstoffe
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
PL346767A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
DE69526584D1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
EA199900363A1 (ru) Новые производные пентаэритрита, их получение и применение, а также промежуточные продукты для их синтеза
MX9701532A (es) Procedimiento para aumentar los niveles de testosterona.
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
UA9522A (uk) Спосіб лікування аутоімунного тиреоідиту
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties